Welcome to Elusys Therapeutics, Inc.

We are committed to developing new biotherapeutic products that dramatically improve treatment of life-threatening infectious disease.

 

Anthim, an anthrax anti-toxin with life-saving potential, has reached a late stage of development. Elusys has recently signed a contract totaling up to $143 Million to complete the final development, commercial manufacturing and licensure of Anthim. learn more

 

 

 

ANTHIM®
Highly effective in treating anthrax-infected animals, Anthim is in late-stage product development.

learn more >>

 

 

Elusys & Biodefense
Elusys has received a contract totaling up to $143 Million to complete the final development, commercial manufacturing and licensure of Anthim.

learn more >>

 

Anthrax & Bioterrorism
Anthrax remains the number one bioterrorism threat. Development of effective new therapies are essential to
protect Americans.

learn more >>

NEWS

September 22nd, 2014
Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (Eti-204)...
read more >>

April 8th, 2014
Elusys Completes Commercial Manufacturing Process Validation for Anthrax Antitoxin ETI-204
read more >>

Elusys Therapuetics, Inc.
voted one of the best places to work in New Jersey.

LEARN MORE ABOUT...

Anthim and Anthrax
See how Anthim prevents cell death from anthrax toxin
view animation >>

Working at Elusys
A dynamic, creative environment to advance your career
learn more >>

Biodefense
Important Information on biodefense and emergency preparedness
learn more >>